Impaired humoral immunity following COVID-19 vaccination in HTLV-1 carriers
Abstract Background Whether human T-lymphotropic virus type 1 (HTLV-1) carriers can develop sufficient humoral immunity after coronavirus disease 2019 (COVID-19) vaccination is unknown. Methods To investigate humoral immunity after COVID-19 vaccination in HTLV-1 carriers, a multicenter, prospective...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-01-01
|
| Series: | BMC Infectious Diseases |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12879-024-09001-z |
| _version_ | 1797350173281615872 |
|---|---|
| author | Takuro Kameda Atae Utsunomiya Nobuaki Otsuka Yoko Kubuki Taisuke Uchida Kotaro Shide Ayako Kamiunten Nobuaki Nakano Masahito Tokunaga Takayoshi Miyazono Yoshikiyo Ito Kentaro Yonekura Toshiro Kawakita Keiichi Akizuki Yuki Tahira Masayoshi Karasawa Tomonori Hidaka Ayaka Konagata Norifumi Taniguchi Yuma Nagatomo Fumiko Kogo Koichiro Shimizu Hiroaki Ueno Junzo Ishizaki Naoya Takahashi Yoshihiko Ikei Michihiro Hidaka Hideki Yamaguchi Kazuya Shimoda |
| author_facet | Takuro Kameda Atae Utsunomiya Nobuaki Otsuka Yoko Kubuki Taisuke Uchida Kotaro Shide Ayako Kamiunten Nobuaki Nakano Masahito Tokunaga Takayoshi Miyazono Yoshikiyo Ito Kentaro Yonekura Toshiro Kawakita Keiichi Akizuki Yuki Tahira Masayoshi Karasawa Tomonori Hidaka Ayaka Konagata Norifumi Taniguchi Yuma Nagatomo Fumiko Kogo Koichiro Shimizu Hiroaki Ueno Junzo Ishizaki Naoya Takahashi Yoshihiko Ikei Michihiro Hidaka Hideki Yamaguchi Kazuya Shimoda |
| author_sort | Takuro Kameda |
| collection | DOAJ |
| description | Abstract Background Whether human T-lymphotropic virus type 1 (HTLV-1) carriers can develop sufficient humoral immunity after coronavirus disease 2019 (COVID-19) vaccination is unknown. Methods To investigate humoral immunity after COVID-19 vaccination in HTLV-1 carriers, a multicenter, prospective observational cohort study was conducted at five institutions in southwestern Japan, an endemic area for HTLV-1. HTLV-1 carriers and HTLV-1-negative controls were enrolled for this study from January to December 2022. During this period, the third dose of the COVID-19 vaccine was actively administered. HTLV-1 carriers were enrolled during outpatient visits, while HTLV-1-negative controls included health care workers and patients treated by participating institutions for diabetes, hypertension, or dyslipidemia. The main outcome was the effect of HTLV-1 infection on the plasma anti-COVID-19 spike IgG (IgG-S) titers after the third dose, assessed by multivariate linear regression with other clinical factors. Results We analyzed 181 cases (90 HTLV-1 carriers, 91 HTLV-1-negative controls) after receiving the third dose. HTLV-1 carriers were older (median age 67.0 vs. 45.0 years, p < 0.001) and more frequently had diabetes, hypertension, or dyslipidemia than did HTLV-1-negative controls (60.0% vs. 27.5%, p < 0.001). After the third dose, the IgG-S titers decreased over time in both carriers and controls. Multivariate linear regression in the entire cohort showed that time since the third dose, age, and HTLV-1 infection negatively influenced IgG-S titers. After adjusting for confounders such as age, or presence of diabetes, hypertension, or dyslipidemia between carriers and controls using the overlap weighting propensity score method, and performing weighted regression analysis in the entire cohort, both time since the third dose and HTLV-1 infection negatively influenced IgG-S titers. Conclusions The humoral immunity after the third vaccination dose is impaired in HTLV-1 carriers; thus, customized vaccination schedules may be necessary for them. |
| first_indexed | 2024-03-08T12:40:55Z |
| format | Article |
| id | doaj.art-fdd59268132d4c69ade668b326b96f2c |
| institution | Directory Open Access Journal |
| issn | 1471-2334 |
| language | English |
| last_indexed | 2024-03-08T12:40:55Z |
| publishDate | 2024-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Infectious Diseases |
| spelling | doaj.art-fdd59268132d4c69ade668b326b96f2c2024-01-21T12:12:15ZengBMCBMC Infectious Diseases1471-23342024-01-012411810.1186/s12879-024-09001-zImpaired humoral immunity following COVID-19 vaccination in HTLV-1 carriersTakuro Kameda0Atae Utsunomiya1Nobuaki Otsuka2Yoko Kubuki3Taisuke Uchida4Kotaro Shide5Ayako Kamiunten6Nobuaki Nakano7Masahito Tokunaga8Takayoshi Miyazono9Yoshikiyo Ito10Kentaro Yonekura11Toshiro Kawakita12Keiichi Akizuki13Yuki Tahira14Masayoshi Karasawa15Tomonori Hidaka16Ayaka Konagata17Norifumi Taniguchi18Yuma Nagatomo19Fumiko Kogo20Koichiro Shimizu21Hiroaki Ueno22Junzo Ishizaki23Naoya Takahashi24Yoshihiko Ikei25Michihiro Hidaka26Hideki Yamaguchi27Kazuya Shimoda28Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of MiyazakiDepartment of Hematology, Imamura General HospitalYoukikai Ikei HospitalDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of MiyazakiDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of MiyazakiDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of MiyazakiDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of MiyazakiDepartment of Hematology, Imamura General HospitalDepartment of Hematology, Imamura General HospitalDepartment of Hematology, Imamura General HospitalDepartment of Hematology, Imamura General HospitalDepartment of Dermatology, Imamura General HospitalNational Hospital Organization Kumamoto Medical CenterDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of MiyazakiDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of MiyazakiDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of MiyazakiDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of MiyazakiDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of MiyazakiDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of MiyazakiDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of MiyazakiDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of MiyazakiDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of MiyazakiDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of MiyazakiDepartment of Internal Medicine, Aisenkai Nichinan HospitalYoukikai Ikei HospitalYoukikai Ikei HospitalNational Hospital Organization Kumamoto Medical CenterDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of MiyazakiDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of MiyazakiAbstract Background Whether human T-lymphotropic virus type 1 (HTLV-1) carriers can develop sufficient humoral immunity after coronavirus disease 2019 (COVID-19) vaccination is unknown. Methods To investigate humoral immunity after COVID-19 vaccination in HTLV-1 carriers, a multicenter, prospective observational cohort study was conducted at five institutions in southwestern Japan, an endemic area for HTLV-1. HTLV-1 carriers and HTLV-1-negative controls were enrolled for this study from January to December 2022. During this period, the third dose of the COVID-19 vaccine was actively administered. HTLV-1 carriers were enrolled during outpatient visits, while HTLV-1-negative controls included health care workers and patients treated by participating institutions for diabetes, hypertension, or dyslipidemia. The main outcome was the effect of HTLV-1 infection on the plasma anti-COVID-19 spike IgG (IgG-S) titers after the third dose, assessed by multivariate linear regression with other clinical factors. Results We analyzed 181 cases (90 HTLV-1 carriers, 91 HTLV-1-negative controls) after receiving the third dose. HTLV-1 carriers were older (median age 67.0 vs. 45.0 years, p < 0.001) and more frequently had diabetes, hypertension, or dyslipidemia than did HTLV-1-negative controls (60.0% vs. 27.5%, p < 0.001). After the third dose, the IgG-S titers decreased over time in both carriers and controls. Multivariate linear regression in the entire cohort showed that time since the third dose, age, and HTLV-1 infection negatively influenced IgG-S titers. After adjusting for confounders such as age, or presence of diabetes, hypertension, or dyslipidemia between carriers and controls using the overlap weighting propensity score method, and performing weighted regression analysis in the entire cohort, both time since the third dose and HTLV-1 infection negatively influenced IgG-S titers. Conclusions The humoral immunity after the third vaccination dose is impaired in HTLV-1 carriers; thus, customized vaccination schedules may be necessary for them.https://doi.org/10.1186/s12879-024-09001-zCOVID-19HTLV-1SARS-COV-2 spike proteinHumoral immunityVaccination |
| spellingShingle | Takuro Kameda Atae Utsunomiya Nobuaki Otsuka Yoko Kubuki Taisuke Uchida Kotaro Shide Ayako Kamiunten Nobuaki Nakano Masahito Tokunaga Takayoshi Miyazono Yoshikiyo Ito Kentaro Yonekura Toshiro Kawakita Keiichi Akizuki Yuki Tahira Masayoshi Karasawa Tomonori Hidaka Ayaka Konagata Norifumi Taniguchi Yuma Nagatomo Fumiko Kogo Koichiro Shimizu Hiroaki Ueno Junzo Ishizaki Naoya Takahashi Yoshihiko Ikei Michihiro Hidaka Hideki Yamaguchi Kazuya Shimoda Impaired humoral immunity following COVID-19 vaccination in HTLV-1 carriers BMC Infectious Diseases COVID-19 HTLV-1 SARS-COV-2 spike protein Humoral immunity Vaccination |
| title | Impaired humoral immunity following COVID-19 vaccination in HTLV-1 carriers |
| title_full | Impaired humoral immunity following COVID-19 vaccination in HTLV-1 carriers |
| title_fullStr | Impaired humoral immunity following COVID-19 vaccination in HTLV-1 carriers |
| title_full_unstemmed | Impaired humoral immunity following COVID-19 vaccination in HTLV-1 carriers |
| title_short | Impaired humoral immunity following COVID-19 vaccination in HTLV-1 carriers |
| title_sort | impaired humoral immunity following covid 19 vaccination in htlv 1 carriers |
| topic | COVID-19 HTLV-1 SARS-COV-2 spike protein Humoral immunity Vaccination |
| url | https://doi.org/10.1186/s12879-024-09001-z |
| work_keys_str_mv | AT takurokameda impairedhumoralimmunityfollowingcovid19vaccinationinhtlv1carriers AT ataeutsunomiya impairedhumoralimmunityfollowingcovid19vaccinationinhtlv1carriers AT nobuakiotsuka impairedhumoralimmunityfollowingcovid19vaccinationinhtlv1carriers AT yokokubuki impairedhumoralimmunityfollowingcovid19vaccinationinhtlv1carriers AT taisukeuchida impairedhumoralimmunityfollowingcovid19vaccinationinhtlv1carriers AT kotaroshide impairedhumoralimmunityfollowingcovid19vaccinationinhtlv1carriers AT ayakokamiunten impairedhumoralimmunityfollowingcovid19vaccinationinhtlv1carriers AT nobuakinakano impairedhumoralimmunityfollowingcovid19vaccinationinhtlv1carriers AT masahitotokunaga impairedhumoralimmunityfollowingcovid19vaccinationinhtlv1carriers AT takayoshimiyazono impairedhumoralimmunityfollowingcovid19vaccinationinhtlv1carriers AT yoshikiyoito impairedhumoralimmunityfollowingcovid19vaccinationinhtlv1carriers AT kentaroyonekura impairedhumoralimmunityfollowingcovid19vaccinationinhtlv1carriers AT toshirokawakita impairedhumoralimmunityfollowingcovid19vaccinationinhtlv1carriers AT keiichiakizuki impairedhumoralimmunityfollowingcovid19vaccinationinhtlv1carriers AT yukitahira impairedhumoralimmunityfollowingcovid19vaccinationinhtlv1carriers AT masayoshikarasawa impairedhumoralimmunityfollowingcovid19vaccinationinhtlv1carriers AT tomonorihidaka impairedhumoralimmunityfollowingcovid19vaccinationinhtlv1carriers AT ayakakonagata impairedhumoralimmunityfollowingcovid19vaccinationinhtlv1carriers AT norifumitaniguchi impairedhumoralimmunityfollowingcovid19vaccinationinhtlv1carriers AT yumanagatomo impairedhumoralimmunityfollowingcovid19vaccinationinhtlv1carriers AT fumikokogo impairedhumoralimmunityfollowingcovid19vaccinationinhtlv1carriers AT koichiroshimizu impairedhumoralimmunityfollowingcovid19vaccinationinhtlv1carriers AT hiroakiueno impairedhumoralimmunityfollowingcovid19vaccinationinhtlv1carriers AT junzoishizaki impairedhumoralimmunityfollowingcovid19vaccinationinhtlv1carriers AT naoyatakahashi impairedhumoralimmunityfollowingcovid19vaccinationinhtlv1carriers AT yoshihikoikei impairedhumoralimmunityfollowingcovid19vaccinationinhtlv1carriers AT michihirohidaka impairedhumoralimmunityfollowingcovid19vaccinationinhtlv1carriers AT hidekiyamaguchi impairedhumoralimmunityfollowingcovid19vaccinationinhtlv1carriers AT kazuyashimoda impairedhumoralimmunityfollowingcovid19vaccinationinhtlv1carriers |